PROMINENT umcg - ViDoe

2.3. Diabetes in heart failure patients

3:11

2.3. Diabetes in heart failure patients

3.1 Personalsed diabetes treatment decisions in primary care

3:08

3.1 Personalsed diabetes treatment decisions in primary care

Introduction to PROMINENT

2:41

Introduction to PROMINENT

3.3 The transferability of a diabetic model

2:59

3.3 The transferability of a diabetic model

3.2 Patient preferences and regulatory

3:04

3.2 Patient preferences and regulatory

4.4 Atrial fibrillation and heart failure

2:55

4.4 Atrial fibrillation and heart failure

4.3 Analysis of lifestyle patterns for improvement of diabetes prevention & management

3:05

4.3 Analysis of lifestyle patterns for improvement of diabetes prevention & management

4.1 Integrating multiple effects of single drugs to trailor type 2 diabetes

3:33

4.1 Integrating multiple effects of single drugs to trailor type 2 diabetes

2.2 Developement of antibacterial drugs for diabetic infections

2:56

2.2 Developement of antibacterial drugs for diabetic infections

2.1 Targeting protein-protein interaction of MIF in diabetes

2:00

2.1 Targeting protein-protein interaction of MIF in diabetes

1.6 The role of exocrine-endocrine interactions at the onset of type 1 diabetes

1:54

1.6 The role of exocrine-endocrine interactions at the onset of type 1 diabetes

1.5 Towards precision vascular biomedicine: Microfluidic endothelial- glycocalyx disease models

2:10

1.5 Towards precision vascular biomedicine: Microfluidic endothelial- glycocalyx disease models

1.4 Elevated expression of Pyruvate Kinase M in Giant Cell Arteritis

2:53

1.4 Elevated expression of Pyruvate Kinase M in Giant Cell Arteritis

1.3 Epigenetic regulation of diabetes’ related inflammation

2:24

1.3 Epigenetic regulation of diabetes’ related inflammation

1.2 The impact of bile acids on diabetes

2:26

1.2 The impact of bile acids on diabetes

1.1 Genomic guided drug target discovery in asthma

1:52

1.1 Genomic guided drug target discovery in asthma